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RESEARCH ARTICLE
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gene expression study
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Belgium; cDepartment of Molecular Biotechnology, Ghent University, Ghent, Belgium; dBundeswehr Institute of Radiobiology, Munich,
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Nuclear Chemistry and Technology, Centre for Radiobiology and Biological Dosimetry, Warsaw, Poland; gInstitute of Genetics and Biometry,
Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Germany
ABSTRACT
Purpose: This collaboration of five established European gene expression labs investigated the potential
impact of culture conditions on the transcriptional response of peripheral blood to radiation exposure.
Materials and methods: Blood from one healthy donor was exposed ex vivo to a Cobalt 60 source to
produce a calibration curve in addition to four unknown doses. After exposure, the blood samples
were either diluted with RPMI medium or left untouched. After 24-h incubation at 37 C the diluted
blood samples were lysed, while the undiluted samples were mixed with the preservative RNALater
and all samples were shipped frozen to the participating labs. Samples were processed by each lab
using microarray (one lab) and QRT-PCR (four labs).
Results: We show that although culture conditions affect the total amount of RNA recovered
(p< .0001) and its integrity (p< .0001), it does not significantly affect dose estimates (except for the
true dose at 1.1Gy). Most importantly, the different analysis approaches provide comparable mean
absolute difference of estimated doses relative to the true doses (p¼ .9) and number of out of range
(>0.5Gy) measurements (p¼ .6).
Conclusion: This study confirms the robustness of gene expression as a method for biological
dosimetry.
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Introduction
In the past few years, gene expression exercises have illus-
trated the potential of gene expression for use in biodosime-
try (Badie et al. 2013; Rothkamm et al. 2013; Abend et al.
2016). Dose assessment in irradiated blood samples can be
obtained by either using dose predictive gene or exon signa-
tures (Paul & Amundson 2008; Kabacik et al. 2011; Boldt
et al. 2012; Knops et al. 2012; Lucas et al. 2014; Macaeva
et al. 2016) or by monitoring the modification of transcrip-
tion of single radiation-responsive genes like ferredoxin
reductase (FDXR) (Manning et al. 2013; Abend et al. 2016).
The first gene expression intercomparison exercise of the
Realising the European Network of Biodosimetry (RENEB) con-
sortium involving four different European labs was performed
using blood samples from five healthy donors using an ex
vivo in vitro whole-blood cell culture model (Abend et al.
2016). It provided important information on methodological
and inter-individual variance in gene expression for specific
radiation-responsive genes. For patient blood collection,
PAXgene tubes were used in which blood cells are lysed
immediately, allowing intra-cellular RNA stabilization. The
tubes are convenient for simple collection, transport, and
storage of blood. During this exercise, dose estimates were
provided by some of the participating labs within hours of
receiving the samples with methodological variance among
dose estimates being low (CV 10% for technical replicates).
After having produced robust calibration curves, the cru-
cial question arose of how relevant the ex vivo generated
gene expression data generated are to the in vivo data.
Amundson et al. first measured in vivo responses in blood
from patients undergoing total body irradiation and con-
firmed the transcriptional activation of several previously
identified biomarker genes (Amundson et al. 2004). In the
recent work by Abend et al. (2016), the question of validity
of an in vitro-constructed calibration curve for in vivo dose
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estimation was addressed by assessing the dose to the blood
of prostate patients treated by radiotherapy. Dose estimates
from radiotherapy-treated, locally exposed prostate cancer
patients could completely discriminate exposed from unex-
posed samples. Nevertheless, all Ct-values obtained from in
vivo blood samples were up to 7-fold below the unexposed
ex vivo in vitro values of the calibration curve obtained by
quantitative reverse transcriptase PCR (QRT-PCR) clearly indi-
cating a discrepancy between in vivo and in vitro situations.
It necessitated introducing an in vitro to in vivo correction
factor which was lab dependent to provide the dose
estimates.
In ex vivo studies, several protocols have been used
such as cultured peripheral blood mononuclear cells
(PBMC) (Dressman et al. 2007; Meadows et al. 2008, 2010;
Sprung et al. 2011; Boldt et al. 2012; Knops et al. 2012;
Riecke et al. 2012; Macaeva et al. 2016), cultured whole
blood diluted with media (Badie et al. 2013; Brzoska and
Kruszewski 2015, Abend et al. 2016) or undiluted whole
blood (Manning et al. 2013). However, none of these stud-
ies have addressed the role of blood culture methods dur-
ing the incubation time at 37 C following radiation
exposure. Such a comparison would allow the impact, if
any, on the transcriptional response to be studied. A wide
range of methodologies, reagents and analysis techniques
are available for studying gene expression and it is import-
ant to identify external factors, apart from radiation expos-
ure, which may cause ‘artificial’ transcriptional modifications
in ex vivo studies, like culture conditions or the type of
analytical approaches; this is particularly relevant for the
calibration curves generated as they are the reference used
for in vivo dose assessments. This concern was briefly
addressed in Macaeva et al. (2016), where they compared
gene expression levels in their study to others in the lit-
erature and found that despite varying cell types, radiation
quality, dose rate, a core signature of genes was found in
common among the studies. However, the role of ex vivo
blood preservation has yet to be addressed.
In the present study, we study the impact of blood culture
methods following radiation exposure on the expression of
radiation-responsive genes and the effect on dose estimation
of blinded samples. The role of the protocol for blood preser-
vation during the experiments in mimicking as closely as
possible in vivo conditions and its impact on inter-laboratory
comparisons is an important factor worth addressing. The
addition of culture medium supplements could potentially
influence transcriptional changes and artificially modify the
response to radiation compared to the natural in vivo
response. As a consequence, this could introduce differences
between participating labs and most importantly affect the
shape of the calibration curves, hence providing inaccurate
dose estimates. The use of different platforms may also intro-
duce variability in the dose estimates provided, however, in a
recent paper by Macaeva et al. (2016), gene expression pro-
files from different platforms were used and very comparable
gene signatures were obtained. Also, in the first RENEB exer-
cise (Abend et al. 2016) different platforms were also used
and again comparable results were obtained. The purpose of
this exercise was not to use similar platforms hoping for simi-
lar estimates, but rather to use different platforms and inves-
tigate which provides the most accurate estimates. The fact
that all laboratories provided dose estimates which are in
good agreement with each other is a strength and, by itself,
demonstrates the robustness of gene expression as a method
for biological dosimetry.
This work is the second study on gene expression organ-
ized and conducted under the umbrella organization RENEB.
This exercise was conducted by the same four European labs
as in the first RENEB exercise with the addition of the
Institute of Nuclear Chemistry and Technology (INCT) in
Poland (Table 1), thus increasing the assesment of variabil-
ities among labs.
Table 1. General characteristics of technical procedures utilized and experiences of the contributing institutions.
Lab Number, Institution, Location Platform/ Chemistry No. of genes/Fit Gene name
Calibration and
Blind samples
processed
1. IRBBw, Munich, Germany QRT-PCR (TaqMan) 3, Lin, log scale or LQ FDXR, PCNA, DDB2 Together
2. PHE, Chilton, UK QRT-PCR (TaqMan) 3 Lin, log scale or LQ FDXR, CCNG1 Together
3. FZ, J€ulich, Germany/ FBN,
Dummerstorf, Germany
Microarrays 7, Hierarchical clustering 4,
WB, K-nearest neighbour
FDXR, VWCE, TNFSF4, PHLDA3, LGR6,
DOK7, SPATA18
TNFSF4, FDXR, LGR6, VWCE
Together
2, DB, K-nearest neighbour TNFSF4, FDXR Together
6, WB, LQ TNFSF4, FDXR, DOK7, PHLDA3, LGR6,
SPATA18
Together
6, DB LQ TNFSF4, FDXR, PHLDA3, LGR6,
SPATA18, VWCE
Together
4. SCK CEN, Mol, Belgium Custom QPCR arrays
(SYBR Green)
12, DB
Point-to-point fit
DDB2, MDM2, TNFRSF10B, AEN, XPC,
ZMAT3, FDXR, CCNG1, NDUFAF6,
MAMDC4, PHPT1, TRIAP1
Together
17, WB
Point-to-point fit
DDB2, MDM2, TNFRSF10B, AEN, XPC,
ZMAT3, FDXR, BAX, CCNG1,
ASTN2, NDUFAF6, MAMDC4,
PHPT1, ASCC3, TRIAP1, RPS27L,
GADD45A
Together
5. INCT, Warsaw, Poland QRT-PCR (TaqMan) 8, Exponential fit BAX, BBC3, CDKN1A, DDB2, FDXR,
GADD45A, GDF15, TNFSF4
Together
WB: whole blood; DB: diluted blood.for the calibration curves this group used samples sent 3 months earlier and other calibration curves sent together with the blind samples.
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Materials and methods
pH testing of whole blood culture conditions
Peripheral blood from three different donors was drawn into
EDTA tubes. One ml of blood was aliquoted per Greiner
Cryo.sTM 2ml vial tube, allowing for gas exchange. Samples
from the same donor were kept at the same conditions with a
varying time point. Three time-points were tested: 0 h (3 h
after blood drawing), 2 h (5 h after blood drawing), 24 h
(27 h after blood drawing). Three storage conditions were
tested: room temperature (RT), 37 C incubator without CO2
supply, 37 C incubator with CO2 supply. At each time-point
one blood sample per condition was centrifuged for 10min at
1500 g at 4 C. The pH values of plasma were measured imme-
diately after centrifugation using WTW inoLab pH level 1 pH
meter (Weilheim, Germany). All procedures followed were
approved by the local SCK·CEN Ethics Committee and were
carried out in accordance with the ethical standards of the
Helsinki Declaration of 1975, as revised in 2000.
Blood sampling, irradiations and distribution to
participant laboratories
Peripheral blood was taken from one healthy female blood
donor with informed consent and ethical approval from
Berkshire Research Ethics Committee (reference number 09/
HO505/87). The blood sample was collected into an EDTA-
coated tube with one tube per dose. Blood samples were
immediately exposed to a gamma Cobalt 60 source at 37 C
(MRC, Harwell Campus, UK) with a dose-rate of 0.7Gy/min. The
absorbed doses were measured using TLD for each dose. The
doses for the calibration curve were 0, 0.16, 0.41, 0.70, 1.43
and 2.92Gy while blind samples were exposed to doses 0.44,
1.08, 1.89 and 0Gy and labelled A, B, C and D, respectively.
After irradiation, each sample was split to be cultured in two
different conditions. The whole blood culture conditions con-
sisted of 500 ll whole blood on its own while for the diluted
blood conditions whole blood samples were diluted with an
equal volume of Roswell Park Memorial Institute (RPMI) 1640
medium containing 10% FCS in a T75 flask. Both samples for
each dose were then placed in an incubator at 37 C for 24h.
At the 24 h time-point, 1ml RNALater (RiboPureTM RNA
Purification Kit, Ambion, Vilnius, Lithuania) was added to the
500 ll whole blood samples while the diluted blood samples
were processed with QIAamp RNA Blood Mini Kit (Qiagen,
Hilden, Germany) up to step 6 of the manufacturer’s proto-
col, (leukocytes lysed in RLT buffer). Both sets of samples
were then placed on ice or frozen until shipment.
Shipment
Blood samples were sent in polystyrene shipment boxes with
cool packs or dry ice by an overnight courier service.
Samples were sent in two lots: (1) Two test samples were
sent from each culture condition (four samples in total); (2)
The calibration samples from the two culture conditions and
blind samples labelled A, B, C and D were sent to each lab
separately. The temperature in the polystyrene box with cold
packs was measured by temperature loggers.
Shipment conditions for whole blood with RNALater
To test storage conditions during transport, blood was drawn
from three different donors and collected into EDTA tubes.
The blood was aliquoted into tubes and one blood sample
from each donor was placed at (1) RT for 24 h, (2) 20 C for
24 h, (3) in a polystyrene box with cold packs for 24 h, (4) on
wet ice for 24 h, (5) at 20 C for 12 h, then in a polystyrene
box with cold packs for 12 h, and (6) in a polystyrene box
with cold packs for 12 h followed by 12 h at 20 C.
RNA extraction
RNA was extracted from the whole blood samples using the
RiboPureTM RNA Purification Kit (Ambion, Vilnius, Lithuania)
following the manufacturer’s instructions. RNA extraction
from diluted blood samples was performed using QIAamp
RNA Blood Mini Kit (Qiagen, Hilden, Germany) by Labs 1, 2, 3
and 4. Lab 5 used RNeasy Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. In all labs except
for Lab 3, samples were treated with appropriate DNAse I
reagents provided with the RNA extraction kits. Lab 3 instead
used a Trizol step in the protocol which gives rise to a higher
purity of RNA. Further details of RNA isolation, cDNA synthe-
sis and quantification for Labs 4 and 5 are given in Table 2.
Details for the other labs can be found in Abend et al.
(2016).
Analysis
Analyses of microarrays as well as QRT-PCR assays were per-
formed at the labs according to established protocols
(Table 2). Detailed analysis protocols for Labs 1, 2 and 3 are
described in Abend et al. (2016). DNA microarrays (44 k
whole human genome, G4112F, Agilent) were performed
according to the manufacturer’s protocols and as described
in Knops et al. (2012).
Statistical methods
The precision of reported dose estimates was measured by
calculating the mean of the absolute differences (MAD) of
estimated doses to their corresponding true doses.
Descriptive statistics were calculated in Microsoft Excel or
SAS. The analytical statistics (t-test) were performed using
SAS (v.9.2; SAS Institute Inc., Cary, NC). In the case of unequal
variance, we employed the Satterthwaite method imple-
mented in the SAS procedure called ‘PROC TTEST’. Graphs
were created using Sigma Plot 12.5 (Jandel Scientific, Erkrath,
Germany).
Results
Different conditions of whole blood culture have no
effect on blood pH
Different culture conditions and time-points had no significant
effect on the pH of the blood samples from different donors
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(Table 3). We were therefore able to conclude that there is no
pH associated modification of the white blood cell environ-
ment when storing undiluted whole blood for 24 h.
Shipment conditions for whole blood with RNALater
Upon receipt of the test samples which were sent as a pre-
experiment, all four labs to which the same samples were
shipped, reported that after centrifugation whole blood sam-
ples in RNALater would not separate blood from the
RNALater reagent. Instead, there appeared to be a smearing
of the blood sample throughout the tube as shown in
Figure 1(A) preventing efficient lysis to occur; in contrast nor-
mal centrifugations and separation were obtained for the
blood samples prepared in the lab where no shipment was
involved (Figure 1(B)). In order to further investigate this
issue, an experiment was performed to assess the role of the
shipment conditions at RT, 20 C and with cold packs for
three blood donors. Results showed that the smearing of the
blood samples appeared in some samples specifically when
stored with cold packs (Figure 1(C)). Although no explanation
was found, it was decided that subsequent blood samples
would be sent frozen on dry ice.
RNA extraction
RNA of sufficient quality and quantity was extracted from all
samples which were sent on dry ice. The total amount of
RNA appeared comparable between labs with the exception
of diluted blood samples from Lab 3 where 4.21 micrograms
of total RNA was extracted on average compared to 1.34,
1.31, 0.92 and 0.75mg for Labs 1, 2, 4 and 5, respectively
(Table 4). Overall, the total amount of RNA recovered was
significantly higher when extracted from whole blood. A 4-
to 6-fold higher amount of RNA was found for whole blood
(mean for all labs, excluding Lab 3: 6.5 ± 3.1 micrograms
[amount for 500 microliters 2]) compared to diluted blood
(mean of 1.1 ± 0.36, excluding Lab 3). These differences were
of statistical significance (p< .0001). In contrast, the RNA
quality as assessed by obtaining RIN values, was significantly
lower in whole blood samples (mean RIN for Labs 1–4 was
6.8 ± 0.4) compared to diluted blood (mean RIN for Labs 1–4
was 8.9 ± 0.8 [p< .0001]).
Dose estimation
Calibration curves were obtained in each lab using their
own curve fit and results for labs using QRT-PCR are shown
Table 2. Methods used by contributing labs.
QRT-PCR
Lab 4: SCK CEN, Mol, Belgium Lab 5: INCT, Warsaw, Poland
RNA isolation
Isolation kit
DB: QIAamp RNA Blood Mini Kit
WB: RiboPureTM RNA Purification Kit
DB: QIAamp RNA Blood Mini Kitþ RNeasy Mini Kit
WB: RiboPure-Blood Kit
DNA digestion during Isolation DB: RNase-free DNase-Set
WB: DNA-freeTM
DB: RNase-free DNase-Set
WB: DNA-freeTM
Template eluted in Quality Control DB: RNAse-free water;
WB: RiboPureTM Elution Solution
DB: RNAse-free water;
WB: RiboPureTM Elution Solution
RNA integrity number Yes No
Concentration Trinean Xpose Quantus fluorometer
A260/280 Yes No
A260/230 Yes No
Check DNA contamination Yes, Human genomic DNA control No
cDNA Synthesis
Kit/MasterMix
RT2 First Strand Kit High Capacity cDNA Reverse Transcription Kit
RT protocol 1/42 C/15min, 1/95 C/5min 1/25 C/10min, 1/37 C/120min,1/85 C/5min
Quality Control Reverse transcription control ITFG1-CT, DPM1-CT
QRT-PCR
Kit/MasterMix
RT2 SYBRVR Green qPCR Mastermix TaqMan Universal Master Mix II, no UNG
fp/rp/probe Custom RT2 Profiler PCR Array BAX, BBC3, CDKN1A, DDB2, DPM1, FDXR, GADD45A,
interrogating 29 genes (including 4 HKG). GDF15, ITFG1, TNFSF4
Cycles 1/95 C/10min, 40x/95 C/15s&60 C/1min 1/95 C/10min, 40x/95 C/15s&60 C/1min
Detection system Applied Biosystems 7500 Fast Real-Time PCR System 7500 Real-Time PCR System, AB
Fixed/variable threshold Manual fixed Fixed
Normalization HPRT1, PGK1, GAPDH, B2M ITFG1, DPM1
Quantification method Average DCt Nonlinear regression model based on the sum of DCt
Quality Control
Standard curve No No
Slope No No
r2 No No
18SrRNA-CT HPRT1, positive PCR control ITFG1-CT, DPM1-CT, NTC
WB: whole blood; DB: diluted blood.
Table 3. pH levels in whole blood from three donors at
varying time-points and conditions.
Donor Time/condition pH
Donor 1 0 h/RT 7.4
2 h/RT 7.4
24 h/RT 7.5
Donor 2 0 h/37þCO2 7.5
2 h/37þCO2 7.6
24 h/37þCO2 7.4
Donor 3 0 h/37-CO2 7.5
2 h/37-CO2 7.5
24 h/37-CO2 7.6
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in Figure 2. Calibration curves for QRT-PCR labs, obtained
with diluted blood are shown on the left panels and those
obtained with whole blood on the right panels, apart from
Lab 5 where both diluted and whole blood is shown on the
same panel (Figure 2(G)). Overall, the shapes of the calibra-
tion curves are comparable between whole blood and
diluted blood. Intra-laboratory differences are evident
between genes. For example, Lab 1 (Figure 2(A) and (B))
used different calibration curve fits, depending on which
best suited each gene. The best fits for the two genes FDXR
and CCNG1 used in Lab 2 (Figure 2(C) and (D)) are different
although they were analyzed simultaneously in a multiplex
QRT-PCR assay, hence highlighting the gene specificity of the
response to radiation. The fits are therefore gene-dependent
and are not affected by the blood culturing conditions. With
regards to the difference in expression between whole and
diluted blood, the difference can be seen in particular in
Lab 4 (Figure 2(E) and (F)) and is perhaps most evident in
Lab 5 (Figure 2(G)) where the genes are expressed at a
higher Ct level in the whole blood samples. The shapes of
the calibration curves are very similar for Lab 4 but it is the
Ct values that differ, e.g. for MDM2 0Gy starting at 6 Ct for
diluted blood and 8 Ct for whole blood (Figure 2(E) and (F))
(Supplementary Table 1, available online). The different blood
preservation methods therefore seem to affect baseline
expression levels, although the relative expression in
response to radiation remains was overall very similar.
In Figure 3, calibration curves derived from whole and
diluted blood are shown for each of the two genes analyzed
in Lab 2. For FDXR (Figure 3(A)) the best fit is obtained using
a log fit, while a linear quadratic was the best for CCNG1
(Figure 3(B)). Coefficients of determination of the calibration
curves were 0.98 and 0.96 for FDXR, and 0.87 and 0.83 for
CCNG1 for diluted blood and whole blood, respectively. The
normalized absolute gene expression values are on average
slightly higher for diluted blood and this is more pronounced
for FDXR. The normalized gene expression values were plot-
ted versus the true doses of the four blinded samples for
whole blood (white stars and squares) and diluted blood
(filled triangles) and do show a general good fit with the cor-
responding calibration curves. For CCNG1, the dose assess-
ment in the 0–1Gy range is accurate (normalized gene
expression of 6.14 [0 Gy] 14.90 [0.44 Gy] and 23.60 [1.08 Gy],
respectively) but for higher doses, due to the shape of the
calibration curve, estimating the dose accurately becomes
problematic as doses of 1.08 and 1.89Gy could not be discri-
minated (normalized gene expression of 23.60 and 23.64,
respectively). This issue highlights the need for further opti-
mization of gene expression and also the continued search
for novel gene biomarkers which may be useful for covering
a range of doses, dose-rates and time-points. Importantly, it
should be noted that the data presented here were obtained
with blood samples exposed ex vivo and it remains to be
seen if the same would apply in vivo as it is possible that
the plateau phase observed may be due to the experimental
conditions and that it may not be detected in vivo. This is
also true for FDXR but to a lower extent as normalized gene
expression shows a better dose dependency (normalized
gene expression of 0.72, 3.28, 6.50, 6.72 for diluted blood
and 0.2, 1.66, 3.23 and 4.21 for whole blood corresponding
to doses of 0, 0.44, 1.08 and 1.89Gy, respectively). This is
reflected in Table 5 where, although the whole blood MAD
values for both genes are slightly lower (0.2 for whole blood
versus 0.3 for diluted blood), no reported dose estimate is
out by more than 0.5 Gy for whole blood as compared to
diluted blood where doses of 2 and 2.1 were reported (true
dose of 1.08Gy) for FDXR and CCNG1, respectively. Statistical
analysis of dose estimates based on diluted versus whole
blood did not show significant differences in mean values for
true doses such as 0Gy (p¼ .3), 0.4 Gy (p¼ .1) and 1.9 Gy
(p¼ .2). However, mean values at the true dose of 1.1 Gy dif-
fered significantly between dose estimates derived from
diluted (1.6 Gy) and whole blood (0.9 Gy, p¼ .0007). These
significant differences were observed in all labs analyzed and
were not observed at true doses of 1.9 Gy (data not shown).
Results presented in Table 5 summarize the experimental
data generated in the five participating labs obtained by
either QRT-PCR or microarrays. Dose estimates from the QRT-
PCR labs were either provided for a single gene or for a com-
bination of 12 (diluted blood) and 17 (whole blood) genes
(Lab 4), or 8 (Lab 5) genes (Table 5). For Lab 4, MAD values
(A)
Storage   
condition
Donor 1 Donor 2 Donor 3
RT 24 h Separation Separation Separation
-20°C 24 h Separation Separation Separation
Cold packs 24 h No 
Separation
Separation Separation
Wet ice 24 h Separation Separation Separation
-20°C 12 h→
cold packs 12 h
No 
Separation
Separation Separation
Cold packs 12 h
→ -20°C 12 h
No 
Separation
Separation Separation
(C)
(B)
Figure 1. Different shipment conditions of whole blood with RNALater.
(A) Whole blood with RNALater after centrifugation for 1min without shipment.
(B) Whole blood with RNALater after centrifugation for 1min after shipment on
wet ice. (C) Centrifugation results of whole blood with RNALater samples from
three donors at varying storage conditions.
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for a gene signature should only be reflected by one dose
estimate and not for each gene, it was decided to also show
the dose estimates per gene as this reflects the robustness of
the gene expression approach. Lab 1 also performed the
dose estimation using calibration curve samples which were
prepared and sent 3 months earlier which provided very
similar dose estimates to the calibration curve prepared and
used on the same day. It is very useful to know that previ-
ously prepared calibration curves can still provide accurate
dose estimates months after preparation. The precision of
dose estimates using one gene only (e.g. FDXR), as illustrated
for Lab 1 and 2, proved to be as precise as dose estimates
based on up to eight or 17 genes, which were used by Labs
4 and 5. Overall, the 1.1 Gy blinded sample was less well esti-
mated across all contrilaboratories, an effect which was not
observed at higher true dose of 1.9 Gy. Although there is no
identified reason for this, it cannot be excluded that some-
thing happened to this tube during handling and/or irradi-
ation or that it is approaching the upper limit of detection
for gene expression (Abend et al. 2016).
The microarray approach employed (1) hierarchical cluster-
ing, (2) KNN-based dose assessments, and finally (3) dose esti-
mates based on calibration curves of several genes shown in
Figure 4. Hierarchical clustering revealed that all irradiated
whole blood samples resembled more to each other than the
irradiated diluted samples (Figure 4(A)). This strongly suggests
that a large difference exists in the response in terms of gene
expression due to sample preparation. Furthermore, all irradi-
ated samples were more closely related to each other, i.e.
showed more similarities than to their respective control/
non-irradiated sample, irrespective of sample preparation.
Therefore, both blinded D samples were correctly classified as
non-irradiated samples (0Gy) (Figure 4(A) and Table 5).
Figure 4(B), illustrates the applied KNN approach using the
gene expression of the signature genes TNFSF4 and FDXR.
The gene combinations with the highest predictive power,
i.e. the genes TNFSF4, FDXR, LGR6, VWCE for whole blood
samples (four genes) and the genes TNFSF4, FDXR for diluted
blood samples (two genes) classified the test samples A–D
with good precision. The 0.4 Gy-irradiated sample B was clas-
sified as irradiated with 0.5 Gy (diluted blood) and 1Gy
(whole blood) whereas the 1.1 Gy-irradiated sample C was
classified as irradiated with 2Gy for diluted blood, respect-
ively, 1 Gy for whole blood. The 1.9 Gy-irradiated sample D
was correctly classified as a 2Gy-irradiated sample, irrespect-
ive of sample preparation (Table 5). All non-irradiated sam-
ples were correctly classified as unirradiated controls by the
KNN method. Overall, the obtained dose estimations
obtained by KNN classification were very satisfying keeping
in mind that the classification is not based on the calibration
sample data but on microarray data from 2008–2011 derived
from cultured peripheral blood lymphocytes from six non-
related blood donors (for more detail, see Boldt et al. 2012).
The dose estimates derived by regression curve analysis
(Figure 4(C), (D)) from the three most predictive gene combi-
nations for each culture condition were very similar to each
other (Lab 5, regression analysis; Table 5). Moreover, the radi-
ation doses of all whole blood test samples were assessed
with a very good accuracy, irrespective of the used gene
combinations for the dose assessment. The radiation dose
allocation for whole blood samples based on TNFSF4, FDXR
and DOK7 showed a deviation of only 0.1 Gy for two of the
Table 4. Laboratory intercomparison of RNA quality and quantity.
Lab 1 Lab 2 Lab 3 Lab 4 Lab 5
Dose (Gy) Total RNA (ug) RINa Total RNA (ug) RINa Total RNA (ug) RINa Total RNA (ug) RINa Total RNA (ug) RINa
Diluted Blood 1ml 0 1.3 9.9 1.4 9.1 4.3 7.7 1.2 8.8 0.7 N/A
0.16 1.7 9.9 1.3 9.1 5.6 8.3 1.3 9.3 0.6 N/A
0.41 1.7 9.6 1.7 9.2 5.5 8.2 1.2 9.0 0.8 N/A
0.7 1.7 9.8 1.6 9.3 6.1 7.5 1.1 9.0 1.0 N/A
1.43 1.2 9.6 1.6 9.3 4.7 7.0 0.9 8.7 1.0 N/A
2.92 1.5 9.4 1.3 9.3 4.5 7.5 0.8 8.6 0.8 N/A
Blind A 1.2 10.0 1.1 9.2 2.6 8.1 0.9 9.1 0.8 N/A
Blind B 1.1 10.0 1.0 9.2 2.8 8.3 0.6 8.8 0.9 N/A
Blind C 0.9 9.8 1.1 9.4 2.6 7.7 0.5 9.1 0.1 N/A
Blind D 1.1 10.0 1.0 9.2 3.4 7.5 0.7 8.5 0.8 N/A
Diluted Blood 1ml 0 1.4 9.5
(25.11.2015) 0.25 1.2 9.6
0.5 1.0 9.3
1 0.8 9.8
2 0.9 9.7
3 0.7 9.9
4 0.7 8.8
Whole Blood 1ml 0 11.0 6.7 3.3 6.2 6.8 7.1 10.3 7.2 4.6 N/A
0.16 10.8 6.5 5.9 6.5 8.9 5.3 6.5 7.2 4.8 N/A
0.41 5.5 6.9 5.9 6.5 8.6 6.8 9.1 7.1 5.0 N/A
0.7 10.4 6.5 4.9 6.5 10.2 6.7 7.1 7.1 4.8 N/A
1.43 12.0 6.5 6.0 6.5 7.3 6.8 7.4 6.9 5.0 N/A
2.92 12.7 6.5 5.1 6.5 8.6 7.2 6.6 7.0 3.4 N/A
Blind A 12.8 6.4 4.1 6.8 5.3 6.9 3.8 7.5 2.6 N/A
Blind B 11.0 6.5 5.3 6.8 6.6 7.1 4.3 7.2 2.9 N/A
Blind C 11.7 6.5 3.8 6.7 6.2 7.2 4.0 7.4 3.6 N/A
Blind D 11.7 6.5 4.2 6.8 4.5 6.9 4.8 7.6 3.1 N/A
RIN: RNA integrity number.Original volume of 500ul was sent to each lab for analysis. RNA (ug) is calculated per 1ml for comparison.
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four samples and allocated the dose for the other two sam-
ples correctly. The radiation dose for three of the diluted
blood samples was also assessed with good accuracy
(0.5 Gy), while the radiation dose to the diluted blood
sample B was overestimated by >1Gy, irrespective of the
used gene combination.
When analyzing the results of all five labs together, the
mean MAD were comparable for diluted and whole blood,
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0.38 (SEM¼ 0.06) and 0.36 (SEM¼ 0.05), respectively, and dif-
fered not significantly (p¼ 0.9). The average number of dose
estimates out of ±0.5 was following the same trend, 1.3
(±0.1) for diluted blood and 1.2 (±0.2) for whole blood
(p¼ 0.6). All labs were able to identify the 0Gy blinded sam-
ple as unirradiated, except for Lab 5 which provided a dose
estimate of 0.1 Gy for the whole blood 0Gy sample. The
most precise dose estimate for an irradiated sample was
given for the 0.4 Gy sample which, similarly to our previous
exercise, again shows that the most accurate dose estimates
are given in the linear phase of the calibration curve of
<1Gy (Abend et al. 2016). Also, precision of dose estimates
based on one gene only (e.g. FDXR with MAD¼ 0.3–0.4 Gy in
different labs) appeared as good as employing gene signa-
tures consisting of up to 17 genes.
Discussion
Monitoring specific gene expression modifications in
response to an exposure to ionising radiation is emerging as
a promising method for biological dosimetry purposes.
However further work is required to learn more about poten-
tial technical issues and to further assess the robustness of
dose estimates by continuing organising inter-laboratory
comparisons. One main purpose of this study was to assess
the potential of using undiluted whole blood as a simple
alternative to blood preservation by medium dilution. This is
an attractive alternative as it is simple and would prevent
potential gene expression variability introduced after dilution.
In order to compare undiluted whole blood with blood
diluted with medium we first verified that whole blood could
be kept for 24 h without pH variations. We observed that pH
values of ex vivo blood kept at 37 C over a period of 24 h
remained unchanged.
As this was an inter-laboratory comparison, whole blood
and diluted blood samples prepared at PHE had to be dis-
patched to the other four participating labs. During the pilot
experiment, we unexpectedly found out that the shipment of
whole blood in RNALater on wet ice resulted in what was
described as a smearing/clotting of the blood samples pre-
venting the removal of RNALater by centrifugation in the first
step of RNA extraction. This was problematic as RNA extrac-
tion proved almost impossible with very low yields recov-
ered. This whole blood sample clotting was reported in all
four labs which received shipped samples. After investigation
of different shipment temperatures, it appeared that clotting
only occurred when the samples were stored with cold
packs. Interestingly, it seemed that sample clotting was
donor-dependent, although this would require further con-
firmation. One hypothesis is that low temperatures and pres-
sure differences experienced during the flight may cause a
precipitation of the salts and lysis of the cells in the
RNALater solution, as results from the temperature loggers
revealed that the temperatures in the polystyrene shipment
box ranged from 22.5 to 3.5 C (data not shown) during
shipment with cold packs. This smearing of samples was also
apparent after transportation at RT, which is why we decided
to ship samples frozen for the remainder of the exercise. Yet,
in the case of a large scale nuclear accident, issues such as
the availability of dry ice and the cost of shipping parcels
with dry ice could prove problematic. The purpose of send-
ing the blood samples mixed with RNALater is that for sam-
ples collected after in vivo exposure, it is a cheap and simple
alternative to PAXgene tubes. In the case of a nuclear inci-
dent, where potentially thousands of samples would have to
be collected in a short period of time, obtaining such a large
number of tubes might prove to be problematic as they
have a relatively short shelf-life (6 months) and a stock would
have to be periodically renewed which comes at a cost.
Therefore preserving blood RNA in a simple step by adding
RNALater before shipping at RT was an attractive alternative
protocol worth investigating. The fact that it does not seem
to be compatible with being shipped by aeroplane in liquid
form was an unexpected result.
A clear difference in RNA quantity and quality was seen
between whole blood preserved with RNALater and RNA
extraction performed with the Ribopure kit in comparison
with whole blood diluted with medium and RNA extracted
with the QIAamp kit. The Ribopure kit produced a higher
quantity of RNA but it was of lower quality with RINs ranging
between 5.3 and 7.6. While the QIAamp kit produced lower,
yet sufficient quantities of RNA, the quality was consistently
high with RINs of 9–10. However, it is unclear whether the
differences are due to the culture conditions or the extrac-
tion kits as each kit is designed to be suited for the different
culture condition. Although there was a noticeable difference
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between the methods in the RIN values they provided, no
degradation of RNA was evident in either method and all
were of sufficient quality. Although mRNA degradation is a
potential issue, it appears that all samples analyzed in the
present study were of sufficiently good quality to provide
reliable and comparable results. The RNA isolated using both
methods was still of sufficient quantity and quality for each
downstream application. It is nevertheless worth keeping in
mind that the amount of RNA extracted from whole blood
preserved in RNALater is 4- to 6-fold higher, which might be
important in case of limited volume of blood being available.
Overall, both the 1.1 Gy and 1.9Gy samples had the most
dose estimates which fell into the ±0.5 Gy uncertainty inter-
val. This appears to be a limitation of gene expression which
has been previously seen in Manning et al. where the calibra-
tion curves appear to plateau at higher doses (1Gy)
(Manning et al. 2013). Although this issue is also encountered
during established biodosimetry techniques, it generally
occurs at a much higher dose of about 5 Gy (International
Atomic Energy Agency [IAEA] 2011). During a radiation acci-
dent, people are usually exposed to doses of less than 1Gy
(IAEA), the doses at which gene expression is most accurate
Table 5. Reported dose estimates from labs running QRT-PCR or microarrays for each of the samples irradiated with a known (true) dose.
True dose for each
sample (Gy)
MAD
(Gy)
No. of
measurements
out of ±0.5 Gy
True dose for each
sample (Gy)
MAD
(Gy)
No. of
measurements
out of ±0.5 Gy0.0 0.4 1.1 1.9 0.0 0.4 1.1 1.9
Diluted blood Whole blood
Approach: curve fit/gene(s) reported dose estimates (Gy) reported dose estimates (Gy)
Lab 1 Calibration curve, same day
FDXR 0.0 0.6 0.8 1.2 0.3 1 0.0 0.5 0.4 1.3 0.4 2
PCNA 0.0 1.0 1.1 1.4 0.3 2 0.0 0.5 0.1 1.1 0.5 2
DDB2 0.0 0.9 1.0 1.0 0.4 2 0.0 0.5 0.3 0.7 0.5 2
Calibration curve, 3 month earlier
FDXR 0.0 0.4 0.6 0.9 0.4 2
PCNA 0.0 0.8 0.9 1.4 0.3 0
DDB2 0.0 1.2 1.2 1.2 0.4 2
Lab 2 log FDXR 0.0 0.4 2.0 2.1 0.3 1 0.0 0.3 1.3 2.3 0.2 0
LQ CCNG1 0.0 0.6 2.1 2.1 0.3 1 0.0 0.8 1.2 1.7 0.2 0
Lab 3 Hierarchical clustering 0.0 0.2 0.1 0 0.0 0.4 1.4 2.9 0.3 1
Regression analysis
6 (6) genes 0.0 0.8 2.5 2.4 0.6 1 0.0 0.8 1.4 2.1 0.2 0
4 (5) genes 0.0 0.7 2.5 2.3 0.5 1 0.0 0.5 1.3 2.0 0.1 0
2 (3) genes 0.0 0.5 2.3 2.4 0.4 1 0.0 0.5 1.2 1.9 0.1 0
K-nearest neighbour
7 genes 0.0 1.0 2.0 2.0 0.4 2 0.0 0.5 0.5 1.0 0.4 2
5 genes 0.0 1.0 2.0 2.0 0.4 2 0.0 0.5 1.0 1.0 0.3 1
4 genes 0.0 1.0 2.0 2.0 0.4 2 0.0 1.0 1.0 2.0 0.2 1
3 genes (V1) 0.0 0.5 2.0 2.0 0.3 1 0.0 1.0 1.0 2.0 0.2 1
3 genes (V2) 0.0 0.5 1.0 1.0 0.3 1 0.0 0.0 0.0 0.5 0.7 2
2 genes 0.0 0.5 2.0 2.0 0.3 1 0.0 0.0 0.5 0.5 0.6 2
Lab 4 DDB2 0.0 0.4 1.2 2.5 0.2 1 0.0 0.2 2.9 2.9 0.8 2
MDM2 0.2 0.4 2.6 2.9 0.7 2 0.1 0.4 1.8 2.9 0.4 2
TNFRSF10B 0.0 1.7 1.9 2.9 0.8 3 0.1 0.2 0.4 2.9 0.5 2
AEN 0.0 0.4 1.2 2.9 0.3 1 0.1 1.1 2.9 2.9 0.9 3
XPC 0.0 0.4 1.5 2.1 0.1 0 0.0 0.2 2.9 2.9 0.8 2
ZMAT3 0.0 0.4 1.4 1.4 0.2 1 0.1 0.2 0.4 2.9 0.5 2
FDXR 0.0 0.6 1.3 2.9 0.4 1 0.1 0.9 2.9 2.9 0.9 3
CCNG1 0.0 0.4 0.3 2.4 0.3 2 0.0 0.6 0.7 2.9 0.4 1
NDUFAF6 0.0 0.8 2.9 2.9 0.8 2 0.1 1.0 2.9 1.1 0.8 3
MAMDC4 0.0 1.0 1.7 2.5 0.5 3 0.1 0.4 2.9 2.9 0.7 2
PHPT1 0.0 0.7 1.4 1.6 0.2 0 0.0 1.2 2.9 2.9 0.9 3
TRIAP1 0.0 0.4 0.4 2.2 0.2 1 0.1 0.4 2.9 2.9 0.7 2
BAX 0.1 0.8 1.3 2.9 0.4 1
ASTN2 0.1 0.4 1.3 2.5 0.2 1
ASCC3 0.0 0.1 0.3 2.9 0.5 2
RPS27L 0.1 2.9 2.9 2.9 1.4 3
GADD45A 0.1 0.1 1.1 2.9 0.3 1
Integrated over 12 (17) genes 0.0 0.6 1.5 2.4 0.3 0 0.0 0.7 2.0 2.8 0.5 2
Lab 5 Integrated over 8 genes 0.0 0.5 1.1 5.6 0.9 1 0.1 0.2 0.5 0.9 0.5 2
Mean 0.38 1.3 Mean 0.36 1.2
SEM 0.06 0.1 SEM 0.05 0.2
Numbers in bold refer to values used for descriptive statistics (mean and SEM calculation) at the end of the column. Underlines numbers represent values lying
outside the 0.5 Gy interval.
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(Abend et al. 2016). Therefore, this technique, with its fast
report time, is still a useful tool in biodosimetry. The doses
for the unknown samples were chosen with this issue in
mind with a control sample, a dose below 1Gy, a dose
around 1Gy and a dose above 1Gy. These doses investigate
the accuracy in determining a dose estimate for an unex-
posed individual, an individual exposed to a low dose and
two further higher doses which will test the limit of detection
for gene expression.
Some labs used a gene signature for providing dose esti-
mates while others used single genes like FDXR. According to
the data presented, gene signatures performed in a compar-
able way to a single gene approach. This is illustrated by the
consistency in dose estimation across labs. However, gene
signatures provide more robustness due to redundancy and
it is unlikely that a single gene might represent a specific
enough response to ionizing radiation independent of the
time after exposure and potential confounding factors, such
as smoking, gender, chronic irradiation or inflammation. The
use of one female donor for this experiment does introduce
the issue of variability among male and female blood donors.
Previous experiments have found donor sex to be an influ-
encing factor (Kim et al. 2007) and use of a female blood
donor may introduce bias. The focus of this experiment how-
ever, is on blood storage and preparation issues. In order to
prevent variabilities being introduced from other factors, one
donor was used. Donor variability and variability among male
and females has been previously addressed in human blood
Figure 4. Microarray dose estimation approach. (A) K nearest neighbour classification based on the two radiation responsive genes FDXR and TNFSF4. For each test
sample (whole blood sample A–D and diluted blood sample A–D) the three nearest training samples with known radiation doses (0–4 Gy) were determined.
Afterwards, the test sample was assigned to the most frequent radiation dose among its three nearest neighbours. The training samples were derived from ex-situ
irradiated blood from six non-related healthy donors (three males and three females of three age classes; Boldt et al. 2012). Gene expression of FDXR and TNFSF4
are given as Log2 values. (B) Hierarchical clustering of calibration samples and test samples. The heat-map illustrates the radiation-induced expression changes of
the seven signature genes of Lab 3 (Boldt et al. 2012). The hierarchical clustering of the samples (columns) reveals that non-irradiated samples can be easily discri-
minated from irradiated samples (0.16–2.92 Gy). Also, all irradiated whole blood samples as well as all irradiated diluted blood samples form a separate cluster, indi-
cating that sample treatment influences significantly the gene expression response of the signature genes in the irradiated samples. Log2 gene expression values
obtained by DNA microarray analysis are colored from red (low) to white (high). (C, D) Regression curves of the signature genes used for dose assessment in Lab 3.
C – whole blood samples; D – diluted blood samples. Gene expression is given as Log2 value.
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(Manning et al. 2013), although it is unlikely that blood gen-
der would affect blood storage and preparation issues, it is a
question that may need to be further investigated on a
larger scale. Also, the participating labs used their own meth-
ods and data analysis techniques, namely KNN, hierarchical
clustering, use of calibration curves derived from single
genes or genes combined which provided comparable MADs
relative to the true doses and a similar number of out of
range (>0.5 Gy) measurements.
Hierarchical clustering of seven radiation-responsive genes
(Boldt et al. 2012) from microarray results revealed that non-
irradiated samples are very different from irradiated samples,
irrespective of sample preparation (Figure 4(A)). Hierarchical
clustering has previously proven to be very accurate in sepa-
rating irradiated from non-irradiated samples, even at very
low radiation doses such as 20mGy (Knops et al. 2012).
However, sample preparation seems to affect irradiated sam-
ples in a general way. Whole blood samples resemble each
other more in terms of gene expression, irrespective of dose,
than diluted blood samples (Figure 4(B)). This indicates that
the sample preparation influences the gene expression
response after irradiation, at least in the seven genes used
for the clustering approach. This might also indicate that
some factors in the respective solutions interfere substantially
with the radiation damage response of peripheral white
blood cells.
It has been reported many times that the quantification of
gene expression in response to radiation exposure by micro-
array technology is robust and reliable (Paul & Amundson
2008; Boldt et al. 2012; Knops et al. 2012), and the obtained
gene signatures derived in ex situ irradiated blood are shown
to be predictive for the radiation dose in vitro as well as in
vivo (Paul et al. 2011). The gene signature developed by
Boldt et al. (2012) was reported to be robust in terms of
dose prediction. In the current study the KNN approach was
used to predict the radiation dose of the calibration curve
samples as well as of the test samples by comparing them to
this existing data set derived from six healthy non-related
donors. As shown in Figure 4(B), this approach results in a
good accuracy for radiation dose prediction. This is of major
importance because it shows that a satisfying dose classifica-
tion of blood from a non-related donor, either prepared as
whole or diluted blood, is feasible using the independent
gene expression data of six non-related donors. This points
out to an inherent robustness of the seven gene signature
by Boldt et al. (2012). The overall achieved accuracy of the
dose estimates by the KNN methodology is very similar to
the results reported in Abend et al. (2016) by the same
authors.
To summarize the RENEB II exercise, we can conclude that
the data presented here demonstrate that the dose estimates
are always comparable, irrespective of the approach chosen
by the participating labs. Overall, for in vitro studies, we can
conclude that labs can use their favorite protocol for preserv-
ing blood during incubation times as this does not affect the
dose estimates. Dose estimates obtained from diluted or
whole blood are also absolutely comparable. For in vivo stud-
ies, whole blood preserved in RNALater is a cheap and sim-
ple alternative which may be considered for large sample
size analyses. However, calibration curves using different
blood preservation methods are not interchangeable as illus-
trated by the different basal levels of expression between
whole and diluted blood calibration curves. Finally, we
showed that a calibration curve prepared 3 months previ-
ously can be successfully used to provide comparable dose
estimates as the calibration curve generated specifically for
RENEB II (Table 5).
In conclusion, this study brought new data drawing
important conclusions which will be beneficial to future stud-
ies. We are continuing to progress with the learning process
of using gene expression for biological dosimetry purposes
and it continues to show great promise as a method for
accurate and rapid assessment of radiation exposure.
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